Leukemia Panel-AML Mutation, Bone Marrow

The Leukemia Panel-AML Mutation test, performed on bone marrow samples, is designed to detect mutations in the FLT3, NPM1, and CEBPA genes. This assay plays a crucial role in the risk stratification of patients with newly diagnosed cytogenetically normal acute myelogenous leukemia (CN-AML). CN-AML refers to cases where standard cytogenetic analysis does not reveal any chromosomal abnormalities. By analyzing mutations in FLT3, NPM1, and CEBPA, the Leukemia Panel-AML Mutation test helps determine the risk profile and prognosis for individuals with CN-AML. Mutations in FLT3, such as internal tandem duplications (ITD), are associated with a poor prognosis, while NPM1 and CEBPA mutations are considered favorable prognostic markers. This information enables healthcare professionals to make informed treatment decisions and select appropriate therapeutic strategies for CN-AML patients, ultimately improving patient outcomes. Performing the test on bone marrow samples allows for a comprehensive analysis of genetic mutations directly involved in the leukemic process.